Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1-7) mas receptor expression associated with its PPAR-γ agonist action

Free Radic Res. 2011 May;45(5):575-84. doi: 10.3109/10715762.2011.560149. Epub 2011 Mar 7.

Abstract

The beneficial effects of telmisartan on Angiotensin (Ang)-II mediated oxidative stress and renal fibrosis in streptozotocin (STZ)-induced diabetic nephropathy (DN) were studied. Thirty mice were divided into normal (NG), STZ-induced diabetic (DG) and telmisartan-treated diabetic (TG) groups. Compared with NG mice, DG mice showed significant up-regulations of AT-1R, TGF-β1, p-p38MAPK, p-MAPKAPK-2, p-Akt, p47phox, p67phox, gp91phox protein and collagen-III and all of these were significantly reversed in TG mice. The down-regulated protein expression of Ang-(1-7) mas receptor, ACE-2, PPAR-γ and PGC-1α were observed in DG mice and a significant up-regulation effect of telmisartan has been seen in the TG mice. Furthermore, TG mice showed reduced expression of fibronectin, production of superoxide radical as well as renal hypertrophy and fibrosis when compared with DG mice. These findings suggest that Ang-II plays a significant role in DN and telmisartan would be beneficial in reducing oxidative stress and fibrosis in STZ-induced DN.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / metabolism*
  • Angiotensin II Type 1 Receptor Blockers / pharmacology
  • Animals
  • Antioxidants / pharmacology
  • Benzimidazoles / pharmacology*
  • Benzoates / pharmacology*
  • Collagen Type III / drug effects
  • Collagen Type III / metabolism
  • Diabetes Mellitus, Experimental
  • Diabetic Nephropathies / complications
  • Diabetic Nephropathies / drug therapy*
  • Fibrosis
  • Hypertrophy / complications
  • Hypertrophy / drug therapy
  • Intracellular Signaling Peptides and Proteins / drug effects
  • Intracellular Signaling Peptides and Proteins / metabolism
  • Kidney / drug effects
  • Kidney / metabolism
  • Kidney / pathology
  • Mice
  • NADPH Oxidases / drug effects
  • NADPH Oxidases / metabolism
  • Oxidative Stress / drug effects*
  • PPAR gamma / agonists*
  • Peptidyl-Dipeptidase A / drug effects
  • Peptidyl-Dipeptidase A / metabolism
  • Protein Serine-Threonine Kinases / drug effects
  • Protein Serine-Threonine Kinases / metabolism
  • Proto-Oncogene Mas
  • Proto-Oncogene Proteins / drug effects*
  • Proto-Oncogene Proteins / metabolism
  • Receptor, Angiotensin, Type 1 / drug effects
  • Receptor, Angiotensin, Type 1 / metabolism
  • Receptor, Angiotensin, Type 2 / drug effects
  • Receptor, Angiotensin, Type 2 / metabolism
  • Receptors, G-Protein-Coupled / drug effects*
  • Receptors, G-Protein-Coupled / metabolism
  • Superoxides / metabolism
  • Telmisartan
  • Transforming Growth Factor beta1 / drug effects
  • Transforming Growth Factor beta1 / metabolism
  • Up-Regulation / drug effects

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Antioxidants
  • Benzimidazoles
  • Benzoates
  • Collagen Type III
  • Intracellular Signaling Peptides and Proteins
  • PPAR gamma
  • Proto-Oncogene Mas
  • Proto-Oncogene Proteins
  • Receptor, Angiotensin, Type 1
  • Receptor, Angiotensin, Type 2
  • Receptors, G-Protein-Coupled
  • Transforming Growth Factor beta1
  • Superoxides
  • Angiotensin II
  • NADPH Oxidases
  • MAP-kinase-activated kinase 2
  • Protein Serine-Threonine Kinases
  • Peptidyl-Dipeptidase A
  • Telmisartan